Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arrowhead Pharmaceuticals Inc    ARWR

ARROWHEAD PHARMACEUTICALS INC

(ARWR)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

ARROWHEAD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 06:24pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On January 7, 2019, Arrowhead Pharmaceuticals, Inc. (the "Company") and Peter Leone, the Company's Vice President of Strategic Business Initiatives, entered into a separation agreement (the "Agreement") providing for severance payments as set forth below.

Mr. Leone's position with the Company is eliminated and pursuant to the Agreement he shall receive an amount equal to three month's salary from the Company and the Company shall accelerate the vesting of any unvested stock options granted to Mr. Leone during his employment with the Company.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARROWHEAD PHARMACEUTICALS
03/18ARROWHEAD PHARMACEUTICALS : Files IND for Pivotal Phase 2/3 Study of ARO-AAT for..
BU
03/15ARROWHEAD PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Ho..
AQ
03/11ARROWHEAD PHARMACEUTICALS : Begins Dosing in Phase 1 Study of ARO-APOC3 for Trea..
BU
03/04ARROWHEAD PHARMACEUTICALS : to Present at Upcoming March 2019 Conferences
AQ
03/01ARROWHEAD PHARMACEUTICALS : to Present at Upcoming March 2019 Conferences
BU
02/22ARROWHEAD PHARMACEUTICALS : COO Bruce D. Given Sells 242,834 Shares
AQ
02/11ARROWHEAD PHARMACEUTICALS : ARWR) COO Sells $614,390.40 in Stock
AQ
02/07ARROWHEAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
02/07ARROWHEAD PHARMACEUTICALS, INC. : Results of Operations and Financial Condition,..
AQ
02/07ARROWHEAD PHARMACEUTICALS : Reports Fiscal 2019 First Quarter Results
BU
More news
Financials ($)
Sales 2019 195 M
EBIT 2019 97,0 M
Net income 2019 100 M
Finance 2019 4,57 M
Yield 2019 -
P/E ratio 2019 17,16
P/E ratio 2020
Capi. / Sales 2019 8,58x
Capi. / Sales 2020 22,0x
Capitalization 1 674 M
Chart ARROWHEAD PHARMACEUTICALS INC
Duration : Period :
Arrowhead Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARROWHEAD PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 24,3 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Christopher Richard Anzalone President, Chief Executive Officer & Director
Douglass B. Given Chairman
Bruce D. Given Chief Operating Officer
Kenneth Allen Myszkowski CFO & Principal Accounting Officer
James C. Hamilton Vice President & Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ARROWHEAD PHARMACEUTICALS INC43.08%1 674
GILEAD SCIENCES1.95%81 339
VERTEX PHARMACEUTICALS9.55%46 409
REGENERON PHARMACEUTICALS4.90%42 066
GENMAB8.01%10 747
SAREPTA THERAPEUTICS INC12.03%9 008